Document:

amendment.htm

AMENDMENT ONE TO JOINT VENTURE TERMINATION AGREEMENT

 

 

This Amendment One to Joint Venture Termination Agreement (this “Amendment”) is made as of April 30, 2015 (the “Effective Date”), by and between Cytori Therapeutics, Inc., a Delaware corporation (“Cytori”), and Olympus Corporation, a corporation organized and existing under the laws of Japan (“Olympus”).

 

 

WHEREAS, Cytori and Olympus previous entered into that Joint Venture Termination Agreement dated May 8, 2013, by and between Olympus and Cytori (the “Agreement”); and

 

 

WHEREAS, Cytori and Olympus agree to amend Section 2.4 of the Agreement to alter the timing and amount of the payment options (as provided herein) for the Total Purchase Price to be paid by Cytori to Olympus in exchange for the JV Shares and the Olympus Assets; and

 

 

WHEREAS, Cytori and Olympus agree to amend the definition of Total Purchase Price as specified in Schedule 1.1 be amended to be made consistent with the amendment to Section 2.4 of the Agreement as provided herein; and

 

 

WHEREAS, Cytori and Olympus agree to amend Section 10.2 of the Agreement to modify the date by which any claim for monetary damages directly incurred due to a breach of Section 9.2 may be brought; and

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Cytori and Olympus agree as follows:

 

AMENDMENTS:

	
A.  

	
Section 2.4 of the Agreement is hereby deleted in its entirety and replaced with the  following:

 

	
  

	
“2.4

	
(a) Total Purchase Price.  Cytori and Olympus agree that Cytori shall pay a Total Purchase Price of USD $6 million to Olympus on or before May 8, 2016 in the manner as provided in Section 2.5 of the Agreement and herein. Cytori and Olympus recognize and agree that Cytori has previously paid and shall receive a full credit for payments made toward the Total Purchase Price in the total amount of $2,829,751. The parties hereby agree that the balance of the Total Purchase Price owed by Cytori as of the Effective Date of this Amendment and due on or before May 8, 2016 is USD $3,170,249, which shall be payable in the following installment payments.  Interest calculated at 6% per annum on the balance of the Total Purchase Price shall accrue beginning on May 9, 2015, and shall be payable in the same manner that each of the installment payments set forth below are payable.  Accrued interest shall be payable on the date of the last principal payment:

	
  

	
$1,000,000 USD principal, payable on or prior to May 8, 2015;

	
  

	
$500,000 USD principal, payable on or prior to September 30, 2015;

	
  

	
$500,000 USD principal, payable on or prior to December 31, 2015;

	
  

	
$500,000 USD principal, payable on or prior to March 31, 2016; and

	
  

	
$770,249 USD principal and accrued interest, payable on or prior to May 8, 2016.

(b) Extended Payment Option.  If Cytori fails to pay the full balance of any installment payment under Section 2.4(a) when due, then Cytori will be deemed to exercise the “Extended Payment Option.”  Under the Extended Payment Option, Cytori shall pay Olympus the “Extended Purchase Price” of $16,000,000 on or before March 1, 2020, in the minimal annual payments below, after which Cytori shall have no further obligation with respect to the Extended Payment Option.  Cytori and Olympus recognize and agree that Cytori has previously paid and shall receive a full credit toward the Extended Purchase Price for payments made toward the Total Purchase Price in the total amount of $2,829,751.  Cytori and Olympus recognize and agree that Cytori shall receive a full credit toward the Extended Purchase Price for any amounts (excluding interest) paid toward the Total Purchase Price under the conditions set forth in Section 2.4(a). In the event that Cytori exercises the Extended Payment Option, Cytori shall pay the shortfall in installment payments, including any accrued interest, under Section 2.4(a) in full within sixty (60) days following the end of the Cytori fiscal year in which the shortfall in installment payments occurred, as well as the balance of the Extended Purchase Price in extended installment payments specified below for years 2017 through 2020, as set forth below:

	
  

	
$3,000,000 USD principal amount payable on or prior to March 1, 2017;

	
  

	
$3,000,000 USD principal amount payable on or prior to March 1, 2018;

	
  

	
$4,000,000 USD principal amount payable on or prior to March 1, 2019; and

	
  

	
any additional principal amount necessary to reach a total of $16,000,000 on or prior to March 1, 2020.

(c) Prepayment Option. At any time prior to May 8, 2016, Cytori shall have the option of prepaying the full balance of the Total Purchase Price.  If Cytori exercises this prepayment option, then Cytori shall pay Olympus interest calculated in accordance with Section 2.4(a) on the then remaining balance of the Total Purchase Price through the date on which Cytori pays Olympus such remaining balance of the Total Purchase Price.

	
B.  

	
Schedule 1.1 of the Agreement is hereby amended by deleting the definition of “Total Purchase Price” in its entirety and replacing it with the following definition:

 

“Total Purchase Price” means the purchase price paid by Cytori to Olympus for the JV Shares and the Olympus Assets in the amount of USD $6 million in accordance with Section 2.4 (a), excluding any interest.

 

	
C.  

	
Schedule 1.1 of the Agreement is hereby amended by revising the definition of “Extended Payment Option” and adding a definition of “Extended Purchase Price” as follows:

 

 

“Extended Payment Option” has the meaning ascribed thereto in Section 2.4 (b).

 

“Extended Purchase Price” means the purchase price paid by Cytori to Olympus for the JV Shares and the Olympus Assets in the amount of USD $16 million in accordance with Section 2.4(b).

 

	
D.  

	
Schedule 1.1 of the Agreement  is hereby amended by deleting the definitions of “Olympus Payment Option”, “One Year Payment Option” and  “Two Year Payment Option” in their entirety.

 

 

	
E.  

	
Section 10.2 of the Agreement is hereby amended by changing the date by which any claim for monetary damages directly incurred due to a breach of Section 9.2 may be brought by either party from March 31, 2018 to the Effective Date of this Amendment, as follows:

 

	
  

	
“10.2

	
Limitation on Claims and Liability Cap.  Neither Party may bring or file any claim for breach of Section 7 (Representations and Warranties) or Section 8 (Olympus Warranty Service and Celution One Support Obligations) after the Effective Date of this Amendment .  Except for Cytori’s obligation to pay the Total Purchase Price pursuant to Section 2.4 (Purchase Price), Cytori’s obligations to adhere to the scope of the License as set forth in Section 3.1, and Cytori’s indemnification obligations set forth in Section 11 (Indemnification), the total cumulative monetary liability of either Party for claims arising out of or related to this Agreement shall not exceed USD 1,000,000.  Notwithstanding the foregoing, (i) either Party may bring or file any claim for monetary damages directly incurred due to a breach of Section 9.2 (Confidentiality and Non-Use) until the Effective Date of this Amendment, without any limitation on the amount of such damages, and (ii) the Parties understand and agree that any breaches by Cytori of Section 3.1 (License) or any breaches by either Party Section 9.2 (Confidentiality and Non-Use) will cause the non-breaching Party irreparable injury and damage and therefore, only in relation to breaches or anticipated breaches of Section 3.1 (License) or Section 9.2 (Confidentiality and Non-Use) by a Party, the non-breaching Party is entitled to seek injunctive and equitable relief in addition to all other remedies available to it by law, without the necessity of posting any kind of bond or security, and without any deadline by which such claims must be brought.

 

F.       Section 12.3 of the Agreement shall be revised as follows for notices to be sent to Cytori:

 

“If to Cytori:

 

3020 Callan Road

 

San Diego, California 92121, United States of America

 

Attention: Marc H. Hedrick

 

Facsimile: 858-458-0994

 

E-mail: mhedrick@cytori.com”

 

 

GENERAL TERMS:

 

	
1  

	
This Amendment shall enter into force as of the Effective Date.

 

	
2  

	
All capitalized terms used but not defined herein shall have the meaning set forth in the Agreement.

 

	
3  

	
Except as otherwise expressly provided herein, the Agreement shall otherwise remain in full force and effect.

 

	
4  

	
This Amendment, together with the Agreement (to the extent not amended hereby) and all exhibits thereto and references therein, constitute the entire agreement among the parties and shall supersede any and all previous contracts, arrangements or understandings between the parties with respect to the subject matter herein.

 

	
5  

	
Each party to this Amendment hereby agrees to perform any further acts and to execute and deliver any further documents that may be necessary or required to carry out the intent and provisions of this Amendment and the transactions contemplated hereby.

 

	
6  

	
This Amendment may not be altered, amended or modified in any way unless done so in accordance with the Agreement.

 

	
7  

	
This Amendment may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument, and such counterparts may be delivered electronically by the parties.

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment One to Joint Venture Termination Agreement to be duly executed by their respective duly authorized signatories as of the Effective Date.

 

 

	
OLYMPUS CORPORATION

	
CYTORI THERAPEUTICS INC.

	  	  
	
By: /s/ Hiroyuki Sasa

	
By: /s/ Tiago Girao

	
Name:

Hiroyuki Sasa

Title:

President and Representative Director

	
Name:

Tiago Girão

Title:

Chief Financial OfficerCA Filed by Filing Services Canada Inc. 403-717-3898

 

CERTIFICATIONS

 

I, Paul E. Heney certify that:

 

		1)	I have reviewed this Annual Report on Form
20-F for Bit-X Financial Corp;

 

		2)	Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light
of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

		3)	Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

		4)	The Company's other certifying officer and
I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
Company and have:

 

		a)	designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;

 

		b)	designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles; 

 

		c)	evaluated the effectiveness of the Company's
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and 

 

		d)	disclosed in this report any change in the
Company's internal control over financial reporting that occurred during the period covered by the annual report that has materially
affected, or is reasonably likely to materially affect, the Company's internal controls over financial reporting; and

 

		5)	The Company's other certifying officer and
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and
the audit committee of Company's board of directors (or persons performing the equivalent function):

 

		a)	all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the Company's ability to record, process, summarize and report financial information; and

 

		b)	any fraud, whether or not material, that
involves management or other employees who have a significant role in the Company's internal control over financial reporting.

 

 

 

Date: April 30, 2015

/s/ Paul E. Heney

Paul E. Heney

CEO & Chairman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]